Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff LexingtonCDIX +0.79%27 Cash-to-Debt is 0.03 as of Mar. 2026, which is 67% below its 10-year median of 0.09. GuruFocus rates CDIX with a GF Score™ of 27/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 670 Healthcare Providers & Services companies, Cardiff Lexington ranks worse than 94.18% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cardiff Lexington's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.03.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Cardiff Lexingtoncouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Cardiff Lexington's Cash-to-Debt or its related term are showing as below:
CDIX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.09 Max: 0.53
Current: 0.03
During the past 13 years, Cardiff Lexington's highest Cash to Debt Ratio was 0.53. The lowest was 0.01. And the median was 0.09.
CDIX's Cash-to-Debt is ranked worse than 94.18% of 670
companies
in the Healthcare Providers & Services industry
Industry Median: 0.785
vs CDIX: 0.03
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cardiff Lexington Cash-to-Debt Related Terms
Cardiff Lexington Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Cardiff Lexington's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Care Facilities subindustry, Cardiff Lexington's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Lexington Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cardiff Lexington's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cardiff Lexington's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Lexington (CDIX) has a Cash-to-Debt of 0.03 as of Mar. 2026. This is 67% below median its historical median of 0.09. Over the past decade, Cardiff Lexington's Cash-to-Debt has ranged from 0.01 to 0.53. According to the industry distribution chart, Cardiff Lexington ranks #631 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 94.2%.
Is Cardiff Lexington's Cash-to-Debt too high?
Cardiff Lexington's current Cash-to-Debt of 0.03 is 67% below median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.53. The Healthcare Providers & Services industry median Cash-to-Debt is 0.79. Cardiff Lexington's value of 0.03 is 96.2% below this industry median. Based on the distribution chart, Cardiff Lexington ranks #631 out of 670 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cardiff Lexington has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Lexington's Cash-to-Debt compare to AMS and SYRA?
According to the Healthcare Providers & Services industry distribution chart, Cardiff Lexington ranks #631 out of 670 companies for Cash-to-Debt. This places Cardiff Lexington in the lower half of its industry. The industry median Cash-to-Debt is 0.79. Cardiff Lexington's value of 0.03 is 96.2% below this benchmark. Historically, Cardiff Lexington's own Cash-to-Debt has ranged from 0.01 to 0.53 over the past decade. While the company's 10-year median is 0.09 vs. the industry median of 0.79, Cardiff Lexington has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.79, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Lexington's current Cash-to-Debt of 0.03 is 96.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Lexington's current Cash-to-Debt is 0.03, which is 67% below median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Lexington stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Lexington (CDIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.51 — trading 537.5% above its estimated fair value. The current Cash-to-Debt is 0.03, which is 67% below median its 10-year median of 0.09 and 96.2% below the Healthcare Providers & Services industry median of 0.79. Cardiff Lexington's overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cardiff Lexington (CDIX), the current Cash-to-Debt is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Lexington (CDIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Lexington stock appears to be overvalued.
The current stock price of $0.51 is trading 537.5% above its estimated GF Value™ of $0.08.
GuruFocus considers Cardiff Lexington to be Significantly Overvalued.
Key valuation signals for CDIX:
Cash-to-Debt: 0.03 (67% below median its 10-year median of 0.09)
GF Value™: $0.08 vs. price of $0.51 (537.5% above fair value)
Industry Position: 96.2% below the Healthcare Providers & Services median (#631 of 670)
No single metric tells the full story. See the CDIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Lexington Corp is an acquisition holding company, conducting its operations through its operating subsidiaries. The company has two reportable operating segments; Healthcare (Nova), and Real Estate (Edge View). The Healthcare segment generates all of the company's revenue and provides a full range of diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. The Real estate segment consists of Edge View, a real estate company that owns various acres zoned medium-density residential.
27GF Score
Get the complete analysis for CDIX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIX has been successfully added to your 
